Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JayjayUSA12007on Mar 18, 2018 1:58am

127 Views

Post# 27735136

RE:All the talk and none of you caught on

Link: https://shortdata.ca/?c=theratechnologies-inc.-short-sales&sym=TH.TO

Date	Short Sale Trades	% Total Trades	Short Traded Volume	% Total Traded Volume	Short Traded Value	% Total Traded Value
Jan 1 2018	778	32.242	239,519	37.718	$1,667,626	37.829
Jan 16 2018	1,169	20.200	317,101	21.815	$2,495,301	21.637
Feb 1 2018	1,432	24.930	359,597	28.536	$2,865,459	28.324
Feb 16 2018	1,477	23.950	440,313	27.125	$3,179,904	27.202
Mar 1 2018	780	28.953	207,002	29.203	$1,476,763	29.221
Mar 16 2018	3,452	18.127	1,197,897	17.777	$11,049,208	17.439